Damaris Raymondi
Optometrist · New York, NYNPI 1194107508
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Coopervision Inc. at 30.4% of the total. 2025 is the largest year on record at $17,739, more than ten times the $1,395 reported in 2019. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $328.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$8K
- Sun Pharmaceutical Industries Inc.$5K
- Bausch & Lomb Americas Inc.$5K
- Tarsus Pharmaceuticals, Inc.$3K
- AbbVie$3K
- Johnson & Johnson Vision Care, Inc.$936
- plus $2K from 11 others
What the payments were for
- Consulting fees$8,84034%
- Speaking & faculty fees$11,00042%
- Travel & lodging$1,3305%
- Food & beverage$4,73018%
- Entertainment$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 22 | $7,883 |
| Sun Pharmaceutical Industries Inc. | 7 | $5,201 |
| Bausch & Lomb Americas Inc. | 4 | $5,048 |
| Tarsus Pharmaceuticals, Inc. | 13 | $2,544 |
| AbbVie(2 entities) | 2 | $2,529 |
| Johnson & Johnson Vision Care, Inc. | 9 | $936 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $434 |
| Oyster Point Pharma, Inc. | 2 | $264 |
| Harrow Eye, LLC | 6 | $235 |
| Alcon | 2 | $201 |
| Amgen | 1 | $125 |
| Novartis | 1 | $124 |
| Aerie Pharmaceuticals, Inc. | 1 | $122 |
| Shire North American Group Inc | 1 | $113 |
| Carl Zeiss Meditec, Inc. | 1 | $90 |
| Optos, Inc. | 1 | $65 |
| Sight Sciences, Inc. | 2 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$7,448
- CEQUA$4,922
- BLINK NUTRITEARS$4,800
- XDEMVY$1,325
- Acuvue$632
- TYRVAYA$264
- XIIDRA$238
- BIOTRUE ONE DAY$236
- RESTASIS$129
- TEPEZZA$125
- TRYPTYR$125
- Rhopressa$122
- Rocklatan$122
- ULTRA MULTIFOCAL TORIC$122
- VEVYE$117
How this compares
$25,965 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 429 | $394,814 |
| XdemvyLotilaner | 11 | $21,026 |
| XiidraLifitegrast | 18 | $16,828 |
| CequaCyclosporine | 24 | $14,423 |
| TyrvayaVarenicline Tartrate | 17 | $10,805 |
| VyzultaLatanoprostene Bunod | 23 | $7,689 |
| Cyclosporine | 16 | $5,014 |
| Travoprost | 13 | $1,275 |
| Latanoprost | 159 | $926 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $251 |
| ErythromycinErythromycin Base | 14 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $2,529 | $394,814429 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $5,048 | $24,51741 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,544 | $21,02611 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $5,201 | $14,42324 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $264 | $10,80517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in New York
- Susan ResnickNew York$463K
- Denise WhittamNew York$343K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
- Richard MadonnaNew York$75K
- George ZikosNew York$72K
- Craig TischNew York$59K
- Arthur JungNew York$50K
- Milly MuiNew York$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.